Soon-Ee Cheah, Jian Li, Brian T Tsuji, Alan Forrest, Jürgen B Bulitta, Roger L Nation
Infections caused by multidrug-resistant Acinetobacter baumannii are a major public health problem, and polymyxins are often the last line of therapy for recalcitrant infections by such isolates. The pharmacokinetics of the two clinically used polymyxins, polymyxin B and colistin, differ considerably, since colistin is administered as an inactive prodrug that undergoes slow conversion to colistin. However, the impact of these substantial pharmacokinetic differences on bacterial killing and resistance emergence is poorly understood...
July 2016: Antimicrobial Agents and Chemotherapy